Endogenous Sex Hormones and Risk of Venous Thromboembolism in Young Women

Overview

Journal J Thromb Haemost

Publisher Elsevier

Specialty Hematology

Date 2019 May 5

PMID 31054196

Citations 10

Authors

Luuk J J Scheres

Astrid van Hylckama Vlieg

Bart E P B Ballieux

Bart C J M Fauser

Frits R Rosendaal

Saskia Middeldorp

Suzanne C Cannegieter

Affiliations

Soon will be listed here.

Abstract

Background: The risk of venous thromboembolism (VTE) in young women can predominantly be attributed to exogenous hormone use. The influence of (abnormalities in) endogenous sex hormones, as in polycystic ovary syndrome (PCOS) or primary ovarian insufficiency (POI), on VTE risk is uncertain.

Objectives: Th assess the association between endogenous sex hormone levels and VTE risk.

Methods: Women aged ≤45 years from the MEGA case-control study who provided a blood sample in the absence of exogenous hormone exposure or pregnancy were included. Sex hormone-binding globulin (SHBG), estradiol, follicle-stimulating hormone (FSH) and testosterone were measured. The free androgen index (FAI) and estradiol to testosterone ratio (E:T) were calculated. VTE risk was assessed according to quartiles (Qs) of levels and clinical cut-offs as proxies for PCOS (FAI > 4.5) and POI (FSH > 40 U/L). Logistic regression models were used to estimate adjusted odds ratios (ORs) with 95% confidence intervals (CIs).

Results: Six hundred and sixty-five women (369 cases; 296 controls) were eligible for the analyses. Testosterone and FSH levels, E:T and POI (FSH > 40 U/L vs FSH ≤ 40 U/L) were not associated with VTE risk. For estradiol, VTE risk was increased with levels in Q4 vs Q1 (OR 1.6; 95% CI 1.0-2.5). There was a dose-response relationship between SHBG levels and VTE risk, with the highest OR at Q4 vs Q1: 2.0 (95% CI 1.2-3.3). FAI > 4.5 (PCOS proxy) vs FAI ≤ 4.5 was associated with increased VTE risk (OR 3.3; 95% CI 0.9-11.8).

Conclusions: Estradiol, SHBG and FAI were associated with VTE risk, suggesting a role for endogenous sex hormones in the pathophysiology of VTE in young women.

Citing Articles

The genetic effects of hormones modulated by the Pituitary-Thyroid/Adrenal/Gonadal axis on the risk of developing venous thromboembolism: a mendelian randomization study.

Tian H, Xie C, Teng B, Zeng Q, Zhao Y, Li F BMC Cardiovasc Disord. 2024; 24(1):383.

PMID: 39054435 PMC: 11270940. DOI: 10.1186/s12872-024-04039-y.

Sex hormone-binding globulin exerts sex-related causal effects on lower extremity varicose veins: evidence from gender-stratified Mendelian randomization.

Fan Q, Meng Y, Nie Z, Xie S, Chen C Front Endocrinol (Lausanne). 2023; 14:1230955.

PMID: 38152135 PMC: 10752419. DOI: 10.3389/fendo.2023.1230955.

Causal inference of sex hormone-binding globulin on venous thromboembolism: evidence from Mendelian randomisation.

Wang S, Wang Y, Bai M, Peng Y, Zhou D, Lei P Thromb J. 2023; 21(1):109.

PMID: 37880771 PMC: 10599068. DOI: 10.1186/s12959-023-00553-9.

Risk factors and treatment interventions associated with incomplete thrombus resolution and pulmonary hypertension after pulmonary embolism.

Fang A, Mayorga-Carlin M, Han P, Cassady S, John T, LaRocco A J Vasc Surg Venous Lymphat Disord. 2023; 12(1):101665.

PMID: 37595746 PMC: 10939011. DOI: 10.1016/j.jvsv.2023.08.006.

Cardiovascular disease risk in women with hyperandrogenism, oligomenorrhea/menstrual irregularity or polycystic ovaries (components of polycystic ovary syndrome): a systematic review and meta-analysis.

Lo A, Lo C, Oliver-Williams C Eur Heart J Open. 2023; 3(4):oead061.

PMID: 37404840 PMC: 10317290. DOI: 10.1093/ehjopen/oead061.

References

Scheres L, van Hylckama Vlieg A, Ballieux B, Fauser B, Rosendaal F, Middeldorp S . Endogenous sex hormones and risk of venous thromboembolism in young women. J Thromb Haemost. 2019; 17(8):1297-1304. PMC: 6852478. DOI: 10.1111/jth.14474. View

Harrington L, Marck B, Wiggins K, McKnight B, Heckbert S, Woods N . Cross-sectional association of endogenous steroid hormone, sex hormone-binding globulin, and precursor steroid levels with hemostatic factor levels in postmenopausal women. J Thromb Haemost. 2016; 15(1):80-90. PMC: 5280337. DOI: 10.1111/jth.13554. View

Martinez C, Suissa S, Rietbrock S, Katholing A, Freedman B, Cohen A . Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ. 2016; 355:i5968. PMC: 5130924. DOI: 10.1136/bmj.i5968. View

Schiffer L, Kempegowda P, Arlt W, OReilly M . MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. Eur J Endocrinol. 2017; 177(3):R125-R143. PMC: 5510573. DOI: 10.1530/EJE-17-0124. View

Daan N, Muka T, Koster M, Roeters van Lennep J, Lambalk C, Laven J . Cardiovascular Risk in Women With Premature Ovarian Insufficiency Compared to Premenopausal Women at Middle Age. J Clin Endocrinol Metab. 2016; 101(9):3306-15. DOI: 10.1210/jc.2016-1141. View

Mumoli N, Cei M, Giorgi Pierfranceschi M, Brondi B, Vitale J, Dentali F . Endogenous sex hormone levels in men with unprovoked deep-vein thrombosis. Thromb Haemost. 2015; 114(2):438-9. DOI: 10.1160/TH15-02-0107. View

Toulis K, Goulis D, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou S . Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011; 17(6):741-60. DOI: 10.1093/humupd/dmr025. View

van Hylckama Vlieg A, Helmerhorst F, Vandenbroucke J, Doggen C, Rosendaal F . The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339:b2921. PMC: 2726929. DOI: 10.1136/bmj.b2921. View

Simo R, Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Selva D . Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab. 2015; 26(7):376-83. DOI: 10.1016/j.tem.2015.05.001. View

10.

Naess I, Christiansen S, Romundstad P, Cannegieter S, Rosendaal F, Hammerstrom J . Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007; 5(4):692-9. DOI: 10.1111/j.1538-7836.2007.02450.x. View

11.

Peng Z, Sun Y, Lv X, Zhang H, Liu C, Dai S . Interleukin-6 Levels in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(2):e0148531. PMC: 4746122. DOI: 10.1371/journal.pone.0148531. View

12.

Kluft C, Lansink M . Effect of oral contraceptives on haemostasis variables. Thromb Haemost. 1997; 78(1):315-26. View

13.

Cho L, Kilpatrick E, Jayagopal V, Diver M, Atkin S . Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxf). 2007; 68(3):390-4. DOI: 10.1111/j.1365-2265.2007.03053.x. View

14.

van Rooijen M, Silveira A, Hamsten A, Bremme K . Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol. 2004; 190(2):332-7. DOI: 10.1016/s0002-9378(03)00950-5. View

15.

Barth J, Field H, Yasmin E, Balen A . Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. Eur J Endocrinol. 2009; 162(3):611-5. DOI: 10.1530/EJE-09-0741. View

16.

Roach R, Lijfering W, Rosendaal F, Cannegieter S, le Cessie S . Sex difference in risk of second but not of first venous thrombosis: paradox explained. Circulation. 2013; 129(1):51-6. DOI: 10.1161/CIRCULATIONAHA.113.004768. View

17.

Bezemer I, Doggen C, Vos H, Rosendaal F . No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med. 2007; 167(5):497-501. DOI: 10.1001/archinte.167.5.497. View

18.

Bird S, Hartzema A, Brophy J, Etminan M, Delaney J . Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2012; 185(2):E115-20. PMC: 3563911. DOI: 10.1503/cmaj.120677. View

19.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

20.

van Vliet H, Frolich M, Christella M, Thomassen L, Doggen C, Rosendaal F . Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod. 2004; 20(2):563-8. DOI: 10.1093/humrep/deh612. View